Prognostic Value of the Controlling Nutritional Status (CONUT) Score in Patients with Diffuse Large B-cell Lymphoma: a Meta-analysis

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Date 2025 Jan 29

PMID 39881386

Authors

Jinqiang Zhao

Ying Wu

Affiliations

Soon will be listed here.

Abstract

Background: The significance of the controlling nutritional status (CONUT) score in predicting the prognostic outcomes of diffuse large B-cell lymphoma (DLBCL) has been widely explored, with conflicting results. Therefore, the present meta-analysis aimed to identify the prognostic significance of the CONUT in DLBCL by aggregating current evidence.

Methods: The Web of Science, PubMed, Embase, CNKI and Cochrane Library databases were searched for articles from inception to October 15, 2024. The prognostic value of CONUT for DLBCL was analyzed by determining the pooled hazard ratios (HRs) with 95% confidence intervals (CIs). The Newcastle-Ottawa Scale (NOS) was used to analyze study quality.

Results: Eight studies including 2687 cases were included in this work. The NOS scores of these studies were 7-9 (median, 8), demonstrating high quality. Our analyses revealed that an elevated CONUT score significantly predicted poor overall survival (OS) (HR = 1.63, 95%CI = 1.29-2.05, p < 0.001) and inferior progression-free survival (PFS) (HR=1.22, 95%CI = 1.12-1.33, p < 0.001) in patients with DLBCL. Further, the elevated CONUT score showed a significant correlation with the following clinicopathological factors in DLBCL: Ann Arbor stage III-IV, Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 2-4, presence of extranodal disease, ≥high intermediate National Comprehensive Cancer Network International Prognostic Index (NCCN IPI), presence of B symptoms, elevated lactose dehydrogenase (LDH) levels, and presence of bone marrow infiltration.

Conclusions: An increased CONUT score was dramatically associated with poor OS and PFS in patients with DLBCL, as well as with clinicopathological characteristics representing DLBCL tumor development.

References

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

Lv J, Chen P, Wu J, Hu C . Prognostic value of pretreatment Controlling Nutritional Status score in esophageal cancer: a meta-analysis. Pathol Oncol Res. 2023; 29:1611221. PMC: 10333492. DOI: 10.3389/pore.2023.1611221. View

Baysal M, Bas V, Demirci U, Gulsaran S, Umit E, Kirkizlar H . The Utility of CONUT Score in Diffuse Large B Cell Lymphoma Patients. Niger J Clin Pract. 2021; 24(8):1194-1199. DOI: 10.4103/njcp.njcp_429_20. View

Jansson H, Cornillet M, Bjorkstrom N, Sturesson C, Sparrelid E . Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort. Eur J Surg Oncol. 2019; 46(5):804-810. DOI: 10.1016/j.ejso.2019.12.008. View

Moore D, Peery M, Tobon K, Raheem F, Hwang G, Alhennawi L . New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma. J Oncol Pharm Pract. 2022; 28(8):1848-1858. DOI: 10.1177/10781552221096165. View

Kaneda Y, Kanemura N, Nakamura N, Ikoma Y, Yamaguchi K, Takada E . The pretreatment Controlling Nutritional Status score is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2023; 65(3):339-345. DOI: 10.1080/10428194.2023.2295787. View

Harris L, Patel K, Martin M . Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Int J Mol Sci. 2020; 21(22). PMC: 7698117. DOI: 10.3390/ijms21228553. View

Chimento A, Casaburi I, Avena P, Trotta F, De Luca A, Rago V . Cholesterol and Its Metabolites in Tumor Growth: Therapeutic Potential of Statins in Cancer Treatment. Front Endocrinol (Lausanne). 2019; 9:807. PMC: 6348274. DOI: 10.3389/fendo.2018.00807. View

Sun H, Ma J, Lu J, Yao Z, Ran H, Zhou H . Fibrinogen-to-albumin ratio predicts overall survival of hepatocellular carcinoma. World J Gastrointest Oncol. 2023; 15(9):1662-1672. PMC: 10514720. DOI: 10.4251/wjgo.v15.i9.1662. View

10.

Matsukawa T, Suto K, Kanaya M, Izumiyama K, Minauchi K, Yoshida S . Validation and comparison of prognostic values of GNRI, PNI, and CONUT in newly diagnosed diffuse large B cell lymphoma. Ann Hematol. 2020; 99(12):2859-2868. DOI: 10.1007/s00277-020-04262-5. View

11.

Melchardt T, Egle A, Greil R . How I treat diffuse large B-cell lymphoma. ESMO Open. 2023; 8(1):100750. PMC: 9843196. DOI: 10.1016/j.esmoop.2022.100750. View

12.

Peng P, Chen L, Shen Q, Xu Z, Ding X . Prognostic Nutritional Index (PNI) and Controlling Nutritional Status (CONUT) score for predicting outcomes of breast cancer: A systematic review and meta-analysis. Pak J Med Sci. 2023; 39(5):1535-1541. PMC: 10480717. DOI: 10.12669/pjms.39.5.7781. View

13.

Takagi K, Buettner S, IJzermans J . Prognostic significance of the controlling nutritional status (CONUT) score in patients with colorectal cancer: A systematic review and meta-analysis. Int J Surg. 2020; 78:91-96. DOI: 10.1016/j.ijsu.2020.04.046. View

14.

Abe A, Hayashi H, Ishihama T, Furuta H . Prognostic impact of the prognostic nutritional index in cases of resected oral squamous cell carcinoma: a retrospective study. BMC Oral Health. 2021; 21(1):40. PMC: 7821535. DOI: 10.1186/s12903-021-01394-6. View

15.

Nagata A, Kanemasa Y, Sasaki Y, Nakamura S, Okuya T, Funasaka C . Clinical impact of controlling nutritional status score on the prognosis of patients with diffuse large B-cell lymphoma. Hematol Oncol. 2020; 38(3):309-317. DOI: 10.1002/hon.2732. View

16.

Liu Z, Zhou H, Zhou Y, Yu M, Cheng Y, Li J . Prognostic impact of the Controlling Nutritional Status Score in patients with biliary tract cancer: a systematic review and meta-analysis. Front Oncol. 2023; 13:1240008. PMC: 10471188. DOI: 10.3389/fonc.2023.1240008. View

17.

Go S, Choi B, Park M, Park S, Kang M, Kim H . Prognostic impact of pretreatment skeletal muscle index and CONUT score in diffuse large B-cell Lymphoma. BMC Cancer. 2023; 23(1):1071. PMC: 10629181. DOI: 10.1186/s12885-023-11590-y. View

18.

Xu X, Tian M, Ding C, Xu H, Wang H, Jin X . Skeletal Muscle Index-Based Cachexia Index as a Predictor of Prognosis in Patients With Cancer: A Meta-Analysis and Systematic Review. Nutr Rev. 2024; 83(3):e852-e865. DOI: 10.1093/nutrit/nuae094. View

19.

Engblom C, Pfirschke C, Pittet M . The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016; 16(7):447-62. DOI: 10.1038/nrc.2016.54. View

20.

Argiles J . Cancer-associated malnutrition. Eur J Oncol Nurs. 2006; 9 Suppl 2:S39-50. DOI: 10.1016/j.ejon.2005.09.006. View